Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 18;3(6):e163.
doi: 10.1097/TXD.0000000000000682. eCollection 2017 Jun.

The Effect and Safety of Prostaglandin Administration in Pediatric Liver Transplantation

Céline Lironi  1 , Valérie A McLin  2 , Barbara E Wildhaber  1
Affiliations

The Effect and Safety of Prostaglandin Administration in Pediatric Liver Transplantation

Céline Lironi et al. Transplant Direct. .

Abstract

Background: Prostaglandins are often administered after liver transplantation (LT) to diminish ischemia-reperfusion injury (IRI), to favor liver recovery and to prevent vascular thrombosis. Possible beneficial effects in adult liver recipients are controversial, but the single existing pediatric small case series shows no significant impact of prostaglandin administration after LT. The purpose of this study was to analyze the effect of the prostaglandin dinoprostone in pediatric liver recipients.

Methods: A retrospective analysis of 41 children (<16 years) who underwent LT between March 2008 and December 2013 was performed. Dinoprostone was administered at a rate from 0.1 to a maximum of 0.6 μg/kg per hour immediately after LT and for a maximum of 5 days. Effect of dinoprostone on post-LT IRI and hepatic function up to 60 postoperative days and number of hypotensive episodes were analyzed.

Results: The median cumulative dose of dinoprostone was 28 μg/kg (interquartile range, 23.2). Dinoprostone had no significant effect on post-LT liver function tests and factor V levels at any of the administered dosages. There was no significant association between the total quantity of vasopressor given and the number of hypotensive episodes observed in 8 patients. One patient showed a short-lasting hypotension, possibly related to the administration of dinoprostone.

Conclusions: This study did not show, at any dosage between 0.1 and 0.6 μg/kg per hour, any differences in beneficial or harmful effects of high- or low-dose dinoprostone administered immediately after pediatric LT on markers of IRI, hepatic function, or hypotension.

PubMed Disclaimer

Conflict of interest statement

The authors declare no funding or conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Transversal scatterplot analyses of the cumulative dose of dinoprostone on: A, ALT; B, γGT; C, INR; D, Factor V (%) at day 5 after LT. There was no significant correlation with the measured outcome parameters.
FIGURE 2
FIGURE 2
Longitudinal analyses of each single dose of dinoprostone on: A, ALT; B, γGT; C, INR; D, Factor V (%) up to 60 days after LT. For easier visualization, patients were stratified into 2 groups of cumulative dose of dinoprostone having received less than and greater than 28 μg/kg body weight. There was no significant correlation with the measured outcome parameters up to day 60.
See this image and copyright information in PMC

References

    1. Giostra E, Chen H, Deng H, et al. Prophylactic administration of prostaglandin E1 in liver transplantation: results of a pilot trial. Transplant Proc. 1997;29:2381–2384. - PubMed
    1. Quiroga J, Prieto J. Liver cytoprotection by prostaglandins. Pharmacol Ther. 1993;58:67–91. - PMC - PubMed
    1. Peltekian KM, Makowka L, Williams R, et al. Prostaglandins in liver failure and transplantation: regeneration, immunomodulation, and cytoprotection. Prostaglandins in Liver Transplantation Research Group. Liver Transpl Surg. 1996;2:171–184. - PubMed
    1. Hossain MA, Wakabayashi H, Izuishi K, et al. The role of prostaglandins in liver ischemia-reperfusion injury. Curr Pharm Des. 2006;12:2935–2951. - PubMed
    1. Alevizacos P, Bechstein WO, Rossaint R, et al. Failure of PGE1 to prevent liver allograft reperfusion injury in a prospective randomized trial. Transplant Proc. 1993;25:2545–2546. - PubMed